MyHealthTeam’s Post

Global healthcare company Sanofi has taken measures to integrate patient voice into their research programs. Their concept of ‘patient-centricity’ has allowed them to better develop meaningful healthcare solutions for individuals. Learn more about this process through our interview with Victoria DiBiaso, VP and Head of Patient Informed Development & Health Value Translation. Read the article here: https://lnkd.in/eCUW-2Er #PatientsAsPartners #PatientsasPartnersEU #PatientAdvocacy #Sanofi

Strengthening #healthequity is a key driver of better universal health outcomes, and ensuring people have equal access to relevant health information and care is a top priority of many executives in the #healthcare and #lifesciences industries. To support this critical initiative, #marketers must work to battle misinformation, adopt #digital best practices, and ensure the brands they represent have access to the data to uncover #insights to better engage underserved or vulnerable populations. Join us on April 23 to discover how healthcare marketers can play a critical role by using data to accelerate progress in building more equity. There will be an opportunity to ask questions during the live event. #pharma #data #healthdata

Accelerate healthcare transformation utilizing strategies for preventative, precise, and personalized whole-person care. Register early for the Value-Based Care Summit, October 28-29, 2024 at The Watergate Hotel in Washington, DC. Applications to speak are currently being accepted. Join healthcare providers, health plans, pharmaceutical companies/manufacturers, and regulatory and legislative leaders to discuss novel approaches, innovative models, and mutually beneficial partnerships that drive care delivery transformation and accelerate the transition to value-based care. Attendees will explore innovations and advancements in value-based care including: • Leveraging Diagnostics for Value-Based Care Strategies • Maximizing Emerging Technologies for Value-Based Care • Incorporating Data Analytics and Integration to Coordinate Care and Eliminate Health Inequities • Integrating Behavioral Health into Value-Based Care Models • Prioritizing Patient Engagement and Customer Experience • Optimizing Payment Accuracy, Care Improvements, and Burden Reduction  • Collaborating with Community Health Centers and Public Health Agencies https://lnkd.in/epSKXN76 #valuebasedcare #thincvalue #thINcVBC #VBC

The Foundation's CEO, Jayasree Iyer, delivered a keynote address at the World Evidence, Pricing and Access Congress 2024 yesterday, where she highlighted that industry plays a key role in reducing health disparities by implementing strategies that overcome barriers to access. "Only 1% of patients in low- and middle-income countries #LMICs have access to innovative medicines five years after the product has been launched. I encourage all industry players to consider whether your company's access strategies address unmet #healthcare needs and ensure lifesaving medicines reach patients in LMICs." Learn how the Foundation is mobilising essential healthcare companies to play their part and raise their game on access ➡ https://lnkd.in/e9U5Ukjq #EPAConf #AccesstoMedicine #EquitableAccess #AccesstoHealthcare #GlobalHealth #HealthcareEquity #pharma

Allhamdulliah! Grateful to have attended an insightful webinar on "Polypharmacy and drug interactions" hosted by PillPedia! The session offered valuable insights into various drug-related interactions, enhancing my knowledge and understanding of this critical topic. Appreciate the efforts of PillPedia in organizing such informative events, fostering growth and learning in the healthcare community. #Pillpedia #Polypharmacy #DrugInteractions #HealthcareLearning #WebinarTakeaways"

Our Transformative #Healthcare Markets team at Real Chemistry led by Rita Glaze-Rowe, is focused on continuously evolving hypotheses and finding insights to help our clients diagnose, understand, and plan against seismic shifts like the #GLP-1 market, because this space has far-reaching impact. The team has launched its first product helping #lifesciences leaders act with clarity in the face of the impact GLP-1s are already having. Click below to learn how to access our first report, which uncovers key driving forces in the market that many didn't see coming. #Diabetes #Obesity #WeightManagement

Today, our board member Elena Moya delivered a presentation on why health systems must deliver with patients at Pharma 2024, organised by Reuters Events in Barcelona. During her presentation, she showcased why patient involvement is non-negotiable when it comes to the success of our healthcare systems. Before diving into technical solutions to strengthen the involvement of the patient community, she emphasised the importance of understanding why patient involvement is so crucial and how it adds value to healthcare systems. Patients' practical understanding of healthcare systems is essential in developing services that align with their needs. To make this possible, we need to promote a cultural shift in how we interact with patients. #PatientPerspective

Giovanny Leon opens day two at Pharma 2024 with a case study presentation that uncovers the critical factors influencing patient access and explores data-driven insights that highlight the varying impacts on individuals across different socioeconomic backgrounds. Giovanny addresses the power of adopting a Patient-Centric Commercialization mindset and discusses how this approach can effectively bridge the gaps in healthcare accessibility and affordability, creating a more inclusive healthcare environment for all. #REpharma2024

I posted a comment on this article, but it appears to have been deleted by the owner of the article. I do not understand why. I merely posted a comment highlighting what I believe was not mentioned as to why there is a low availability of innovation in LMICs. This post (and others before it) have a remarkable pattern of throwing the emphasis on innovation asset holders to improve access in LMICs. As a former senior executive who worked across Sub-Saharan Africa for a global pharma company, I always try to 'balance' such posts by highlighting that LMIC governments also need to take action. In this example, I highlighted the high regulatory burden imposed by some of the markets in Sub Saharan Africa: 1. High regulatory fees - presumably to earn foreign exchange (USD). 2. Shorter renewal periods reduced from 5 years down to 3 years - generating more frequent revenue. 3. Manufacturing Site Inspection fees even when the sites are FDA compliant and approved as cGMP. In some cases, they collect the fee but do not inspect. What is the rationale for that, other than to generate revenue? 4. The requirement to carry out local in-market clinical trials that needs the company to appoint a local medically qualified practitioner because they will not deal directly with the corporate medical director. Do they not accept the data submitted to and accepted by FDA and MHRA? 5. Complex labelling requirements such as price, holograms and registration numbers on each pack. This makes for very high Cost of Goods (COGs) for such low volume 'market-specific' packs. This impacts to create low margins on selling prices. 6. Complete apathy towards securing product availability by allowing parallel imports and allowing excessive in-market margins for wholesalers and retailers. 7. Some markets stipulate local manufacturing after a period of time, such as a first or second regulatory renewal. This is extremely costly. Given all these Government factors is it any wonder there is reluctance to bring innovation to LMICs? The reality is that (likely) as much as 80% of global volume sales are in just North America, top 5 EU and Japan. Of the remaining 20%, 80% is likely to be in China and India along with selected North Africa and Latin American markets. From a commercial viewpoint, why would big pharma bother with LMICs to meet an ever-growing list of demands? A more balanced approach is needed when looking at 'access' instead of blaming asset holders.

In the article “Reclaiming Medicines and Health Innovation for Our Health”, published in November 2024 by Friends of Europe, Els Torreele—independent researcher, advisor on global health equity and medical innovation, and member of the Public Pharma for Europe Coalition—explores how Europe’s healthcare innovation system can be reimagined to prioritise genuine public health benefits, equity, and accessibility, rather than being driven solely by economic metrics. In her words: "Technological innovation can lead to new products and revenue streams, but if these do not provide health benefits or are unavailable or unaffordable to individuals or health systems, they are worthless from a health perspective". 🔗Check out the full article: https://lnkd.in/dXXCFVtD #PPfE #PublicPharma #publicpharmaeurope #publicpharmaforeurope